Skip to main content

Table 1 Patient characteristics for each clinical outcome group

From: Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

 

Donors

Sex

Clinical diagnosis

Age

Stage at diagnosis

 

Outcome

Subtype

Bulky/non-bulky

Treatment

Good outcome

GO1

F

NS

UNSP

29

IV

ABVD

PFS

GO2

F

NS

B

41

IIA

Stanford V + Rad

PFS

GO3

F

NS

NB

79

IA

ABVD + Rad

PFS

GO4

F

NS

B

22

IIA

Stanford V + Rad

PFS

GO5

M

NS

NB

43

IIA

ABVD

PFS

GO6

M

NS

B

20

IIA

ABVD+R

PFS

GO7

F

NS

NB

64

IIA

ABVD

PFS

GO8

F

NS

B

51

IIIB

ABVD + Rad

PFS

GO9

F

NS

UNSP

54

IV

ABVD

PFS

GO10

F

NS

UNSP

22

IIA

ABVD

PFS

GO11

F

NS

NB

25

IIA

ABVD

PFS

GO12

F

NS

NB

26

IIB

ABVD

PFS

Poor outcome (CN)

PO1

M

NS

UNSP

48

IIA

ABVD+R (1); R+Bendamustine (2) Zevalin(3)

Rel.

PO2

M

NS

B

24

II

ABVD (1); acc. BEACOPP (4X) std BEACOPP (2X)(2); Bendamustine + R (3); IGEV + Rad (4); BCPAT (5); CR PT

Ref.

PO3

M

NS

UNSP

25

IIB

ABVD (1); ICE X 3 followed by BPCAT +Local Rad (2); CR PT

Rel.

PO4

F

NS

B

25

IIA

ABVD (1); ICE (2X) (2); GVD+R+Rad (3); HCVAD 1A (4); F+ECPOCH TH2 Allogenic (5); CR PT

Ref.

PO5

M

NS

B

49

IV

ABVD + R (1); ICE + R followed by BCPAT (2); R for EBV reactivation (3); CR PT

Ref.

PO6

M

NS

NB

20

IIIB

ABVD+R (1); ICE X 2 (2); IGEV+R × 2 (3); Rad (4); BCPAT (5); CR

Ref.

Poor outcome (CE)

PO1

M

NS

UNSP

31

IIIB

ABVD (1); ABVD (2); CPPV (3); DICE followed by BPCAT (4); HCVAD 1A + 1B (5); FMPAL (5)

Rel.

PO2

F

NS

UNSP

23

II

MOPP+ABVD (1); BEAC conditioning pre auto transplant (2); Rad (3); ICE X 2/ESHAP X 6 (4);

Rel.

PO3

M

NS

UNSP

21

II

ABVD (1); ESHAP x 1 followed by BCPAT (2); Gemcitabine +Navelbine (3); HCVAD X 3A’S followed by FMPAL (4); DLI infusion (5); Revlamid+DLI infusion (6);

Rel.

PO4

F

NS

B

20

IIA

ABVD+Rad (1); ICE+ auto transplant (2); bone resection+Rad (3); WU protocol phase II Revlamid (4); TH2 Study (EPOCH+FR) NCI protocol followed by BEACOPP pre transplant (5); (No rel.)

Rel.

PO5

M

NS

UNSP

30

IIB

ABVD + Rad (1); ICE + Gemzar followed by BPCAT (2); ESHAP X 3 (3); HCVAD X 5 followed by FMPAL (4); Bendamustine (SK Protocol) 08–041 (5)

Rel.

PO6

M

NS

UNSP

49

IIIB

ABVD (1); ICE followed by BCPAT; GVD + R (3); Revlamid (4) SGN-40 × 2 cycles (5); (PD)

Rel.

PO7

M

NS

UNSP

21

IIA

ABVD (1); ESAHP (2); IGEV (3); BEAC + Rad (4); GDP; R+MOPP (5); died of PD.

Rel.